Biogen reported $59.9M in Interest Expense on Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Amgen AMGN:US $ 368M 40M
Biogen BIIB:US $ 59.9M 5.9M
Biomarin Pharmaceutical BMRN:US $ 4.68M 820K
Bristol Myers Squibb BMY:US $ 299M 14M
Eli Lilly And LLY:US $ 81.5M 300K
Esperion Therapeutics ESPR:US $ 14.15M 113K
Gilead Sciences GILD:US $ 229M 13M
Intercept Pharmaceuticals ICPT:US $ 5.24M 1.43M
Marinus Pharmaceuticals MRNS:US 2.63M 22K
Moderna Inc MRNA:US 8M 3M
Neurocrine Biosciences NBIX:US $ 1.2M 1000K
Novartis NOVN:VX 212.16M 10.16M
Pfizer PFE:US $ 311M 18M
Ptc Therapeutics PTCT:US $ 19.48M 2.8M
Regeneron Pharmaceuticals REGN:US $ 15.3M 2.2M
Sarepta Therapeutics SRPT:US $ 14.74M 1.29M
Teva Pharmaceutical TEVA:IT 81.94B 3.31B
United Therapeutics UTHR:US $ 9.2M 3M
Vertex Pharmaceuticals VRTX:US $ 13.7M 900K
YTE INCY:US $ 641K 37K